2 1 Shi Ji Jing Ji Bao Dao·2025-05-07 23:46Group 1: Pharmaceutical Quality Control - Jiangsu Province achieved a drug inspection pass rate of 99.78% in 2024, with 3,937 varieties and 18,310 batches inspected [1] - Regulatory authorities took immediate actions against non-compliant products, including sealing, halting sales, and requiring recalls [1] Group 2: Healthcare Financing and Efficiency - Lanzhou City launched an instant settlement system for medical insurance funds, reducing the settlement period from 30 days to 1 day, significantly easing financial pressure on medical institutions [2] - As of May 6, 2023, the system processed instant settlements amounting to 3.71 million yuan [2] Group 3: Drug Approvals and Developments - BeiGene's new drug BGB-45035 received clinical trial approval for treating nodular prurigo, targeting IRAK4 [4] - AstraZeneca's BTK inhibitor Calquence, in combination with bendamustine and rituximab, was approved in the EU for treating adult patients with MCL [5] Group 4: Biopharmaceutical Financing - In April 2025, the global biopharmaceutical sector completed 139 financing activities, raising over $3.1 billion, with 20 companies securing individual financing exceeding $50 million [7] Group 5: Market Performance - Novo Nordisk reported Q1 2025 revenue of 78.09 billion Danish kroner (approximately $11.22 billion), an 18% year-on-year increase, with semaglutide generating $8.01 billion [8] - The global GLP-1 drug market is projected to exceed $60 billion in 2025, with Novo Nordisk and Eli Lilly competing for market share [8] Group 6: Strategic Partnerships - Eli Lilly entered a significant licensing agreement with Alchemab Therapeutics for the ALS drug ATLX-1282, valued at up to $415 million [10] Group 7: Market Support Initiatives - Hong Kong Stock Exchange launched a "Tech Innovation Line" to assist tech and biotech companies in the listing process [12]